Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma

NCT03203304 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT03203304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03203304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Terminated
Start date
August 25, 2017
Completion date
March 13, 2019
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma